Adherence, Improvement Measure (AIM) System (AIM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01252212|
Recruitment Status : Completed
First Posted : December 2, 2010
Last Update Posted : November 20, 2013
|Condition or disease||Intervention/treatment||Phase|
|Patient Compliance AIDS||Behavioral: SMS medication adherence Behavioral: No SMS adherence reminder||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||99 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Adherence, Improvement Measure (AIM) System; Challenge Topic: 10-MH-101|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||February 2012|
|Actual Study Completion Date :||December 2012|
Experimental: Receiving SMS alerts
The patients randomized to this arm will have a SMS message sent to them regarding medication adherence for antiretroviral medications, anti-hypertensive medications, anti-depressants, hyperglycemic controlling medications and hypercholesterolemia controlling medications as well as life style supportive suggestions.
Behavioral: SMS medication adherence
SMS messages to cell phones.
Other Name: mobile health messages for health conditions and medications
Active Comparator: No SMS messages
The patients randomized to this arm will have a SMS message sent to them regarding healthy life style supportive suggestions.
Behavioral: No SMS adherence reminder
In this arm, patients will be sent supportive lifestyle suggestions to their phone using SMS technology but will not be sent a reminder regarding their medication adherence.
Other Name: No medication adherence or disease specific messages.
- HIV viral load [ Time Frame: 12 month ]The primary analyses of the 12-month trial data will compare the two study groups with respect to (i) change from baseline in CD4 T-cell count; and (ii) proportion of patients whose HIV viral load (VL) level is detectable. We will use repeated-measures analysis techniques to estimate longitudinal prevalence at the population level (via generalized estimating equations) and at the individual levels (via generalized linear mixed models).
- Level of antiretroviral medication in hair [ Time Frame: 12 month ]We will evaluate the antiretroviral level in hair samples from patients to determine compliance with medications.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01252212
|United States, California|
|Ward 86, San Francisco General Hospital|
|San Francisco, California, United States, 94110|
|Principal Investigator:||James Kahn, MD||University of California, San Francisco|